Key Dates

Related Announcements

• October 9, 2020 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). See NOFO PA-20-272.

Issued by

National Cancer Institute (NCI)

Purpose

The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.

Research Objectives

The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) supports a broad range of basic and preclinical research through investigator-initiated projects and focused programs that target specific questions and challenges in cancer biology. These programs include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Epstein Barr Virus Associated Lymphoma Consortium (EALC), the Metabolic Dysregulation and Cancer Risk Program (MeDoC), the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Pediatric Immunotherapy Network (PIN), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.

This NOT announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. Collaborative projects can include investigators within one consortium, across consortia, and/or may include investigators who are not currently supported by the DCB research programs listed above but are collaborating with a member of a DCB led or co-led consortium (i.e. Associate Members). The programmatic goals of each research program may differ; therefore, it is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.

Collaborative projects must include at least one investigator not named as personnel on the parent award who brings unique expertise that is required for the proposed project. The proposed research plan must be within the overall scope of the active parent U54, U24, U01, R37 and/or R01 award and align with the mission of the Division of Cancer Biology. All potential applicants are highly encouraged to contact their NCI Program Director to discuss the planned collaboration and application.

Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

Eligibility and Eligible Individuals (Program Director/Principal Investigator):

1. Awardees/Applicant(s) must hold an active grant or cooperative agreement in the ARTNet, CSBC, TEC, CCBIR, EALC, MeDOC, MetNet, OAC, OMF, PSRC, PDMC, PIN, PS-ON, Program on the Origins of Gastroesophageal Cancers, or TBEL, as awarded under the Notice of Funding Opportunity (NOFOs) listed below.

PAR-17-171; PAR-17-245; PAR-19-101; PAR-19-113; PAR-19-287; RFA-CA-20-029; RFA-CA-20-040; RFA-CA-20-041; RFA-CA-20-042; PAR-20-131; RFA-CA-21-002; RFA-CA-21-021; RFA-CA-21-022; RFA-CA-21-026; RFA-CA-21-027; PAR-21-348; RFA-CA-21-048; RFA-CA-21-049; RFA-CA-21-052; RFA-CA-21-053; RFA-CA-21-054; RFA-CA-21-055; RFA-CA-22-016; PAR-22-234; PAR-22-099; PAR-22-147; PAR-23-281

1. To be eligible, the parent award must be able to receive funds in FY24 and be active throughout the 1-year project period. The parent award must not be in an extension period (e.g., cost or no-cost extension).
2. Collaborative projects must include at least one investigator not named as personnel on the parent award who brings unique expertise that is required for the proposed project.
3. For supplements to parent awards that include multiple program directors/principal investigators (PD/PIs), the supplement may be requested by any or all of the PD/PIs on that award (in accordance with the existing leadership plan) and must be submitted by the awardee institution of the parent award.
4. One Administrative Supplement application may be submitted by each U01 or R01 parent award. If more than one application is submitted from a given U01 or R01 parent award all applications will be administratively withdrawn from consideration.
5. Up to two Administrative Supplement applications may be submitted by each U24 and U54 parent award. If more than two applications are submitted from a given U24 or U54 parent award all applications will be administratively withdrawn from consideration.
6. Early Stage Investigators (ESIs) are encouraged to apply as part of collaborative teams.
7. Collaborations with foreign institutions are allowed, but investigators must provide a justification for the collaboration. Please note that some foreign collaborations will require U.S. State Department approval by the NCI, and that may delay receipt of funding.

Application Due Date:

All requests, regardless of parent award funding mechanism, must be received by 5:00 PM local time on April 12, 2024. This is a one-time announcement. Late applications will not be accepted.

Budget:

1. Supplement budget request must reflect the actual needs of the proposed one-year project and are limited to $100,000 direct cost per project (e.g. for a collaboration between two DCB led or co-led program awardees, each could request up to $50,000 in direct cost; for a collaborative project that includes a sub-contract, the parent DCB research program award could request up to $100,000 in direct cost to support the collaboration).
2. At least one full year on the parent grant must remain at the time of funding. The supplement application budget is limited to one year only.
3. The earliest anticipated start date is August 1, 2024.
4. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted.
5. If the budget includes a request for salary support, it should include a justification and clear details on what each person will be responsible for. If supporting students and/or postdocs, please indicate if they are already working in the lab or when they will be recruited. A description of how the student/postdoc will be supported after the conclusion of the one-year supplement must be included. It is not appropriate to have TBN personnel listed as part of the budget request. Including support for a patient or research advocate or community partner to collaborate on a supplemental project is acceptable.
6. The administrative supplement awards pursuant to this opportunity are contingent upon the availability of funds from NCI and the receipt of a sufficient number of meritorious requests.

Submitting Applications:

1. The supplement application title should be distinct from that of the parent award and should reflect the content of the supplement proposal.
2. Applicants should begin the supplement application abstract by stating “This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-24-029.”
3. For funding consideration, applicants must include “NOT-CA-24-029” (without quotation marks) in the Agency Routing Identifier field (box 4b) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.
4. Page limits: The Research Strategy section of the application is limited to 3 pages (excluding references). If previous DCB research program collaborative administrative supplements were obtained by the applicant under NOT-CA-22-058 and/or NOT-CA-23-045, a statement of progress is required and an additional 1-page is allowed to outline the results of previous awards.
5. Applications for collaborative projects should be submitted from the individual ARTNet, CSBC, TEC, CCBIR, EALC, MeDOC, MetNet, OAC, OMF, PSRC, PDMC, PIN, PS-ON, Program on the Origins of Gastroesophageal Cancers, or TBEL awardee. For example, for collaborations occurring within the MetNet program each awarded Institution should submit an independent application using the same Research Strategy section but independent budgets that together do not exceed $100,000 direct cost. Similarly, for collaborations occurring across networks (i.e. collaborations involving one PS-ON and one ARTNet investigator), each awarded Institution should submit an independent application using the same Research Strategy section but independent budgets.

Review and Selection Process:

NCI will conduct administrative reviews of applications and will support meritorious applications submitted for consideration based upon the availability of funds.

Specific Review Criteria:

NIH staff will consider the ability of the proposed supplement activities to increase the parent award’s overall impact within the original scope of award and the overall contribution of the collaborative project to program priorities. It is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.

Other criteria that will be considered during review include:

1. The significance of the specific question being pursued within the collaborative project;
2. The requirement for and importance of collaborative research to accomplish the goals of the project;
3. A rigorous study or experimental design with adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects;
4. The applicability of the approach to requirements from the NOFO to which the parent application was submitted (e.g., for an application originating from the MetNet program, does the approach focus on understanding metastasis as a system?);
5. A realistic scope of work, given the time and budget requested;
6. The successful completion of previous administrative supplement projects, if applicable.

Note that projects facilitating new collaborations are of particular interest. Applicants are encouraged to consider how collaborative projects may enhance diverse perspectives within their project teams by introducing new investigators, ideas, and viewpoints. Elevation of an existing project member to key personnel to continue an ongoing collaboration will not be viewed as high priority by NCI.

Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission. Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries related to ARTNet to:

Mihoko Kai
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6257
Email: [email protected]

Please direct inquiries related to CCBIR and TEC to:
Steven Becker
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6210
Email: [email protected]

Please direct inquiries related to CSBC to:
Hannah Dueck
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-5751
Email: [email protected]

Monica Zamisch
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-7311
Email: [email protected]

Please direct inquiries related to EALC to:

Elizabeth Read-Connole 
Division of Cancer Biology 
National Cancer Institute (NCI)
Telephone: 240-276-6190 
Email: [email protected]
 

Please direct inquires related to MeDoC to:

Phil Daschner
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6227
Email: [email protected] 
 

Please direct inquiries related to MetNet or OMF to:
Christine Nadeau
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-7491
Email: [email protected]

Brunilde Gril
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6220
Email: [email protected] 
 

Please direct inquiries related to OAC to:
Margorzata Klauzinska
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6200
Email: [email protected]

Please direct inquiries related to PSRC to:
Tapan Bera
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-5872
Email: [email protected]

Please direct inquiries related to PDMC to:
Konstantin Salnikow
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6230
Email: [email protected]

Please direct inquiries related to PS-ON to:
Eric Johnson Chavarria
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6333
Email: [email protected]

Please direct inquiries related to the Program on the Origins of Gastroesophageal Cancers to:
Rihab Yassin
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6230
Email: [email protected]

Please direct inquiries related to TBEL to:
Elisa Woodhouse
Division of Cancer Biology
National Cancer Institute (NCI)
Telephone: 240-276-6220
Email: [email protected]